Discover how Chroma is expanding our impact.

Boston, MA, May 20, 2024 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-course epigenetic editing therapeutics, today announced the appointment of Jenny Marlowe, Ph.D., as the Company’s Chief Development Officer. Dr. Marlowe is a seasoned biopharma executive and scientific leader with deep expertise in translational, preclinical development, and preclinical safety across multiple genomic medicine modalities.  “I am thrilled to welcome Jenny to Chroma,” said Catherine Stehman-Breen, M.D., CEO of Chroma. “Jenny joins our team at a pivotal time as we prepare to transition to the clinic. Her leadership, experience, and expertise will be instrumental as we work to bring…

Boston, December 10, 2023 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today presented data demonstrating the potential of its multiplex epigenetic editing platform to enhance functional allogeneic chimeric antigen receptor (CAR) T cells at the American Society of Hematology (ASH) 65th Annual Meeting in San Diego. Allogeneic CAR T cell products offer advantages over autologous CAR T cells and have the potential to broaden access to cancer immunotherapy; however, their clinical effect remains limited by lack of durable response and challenges related to immunogenicity and graft-versus-host disease. Incorporating additional edits may help produce…

Boston, November 11, 2023 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today presented new preclinical data demonstrating that a single administration of its epigenetic editor efficiently and durably lowered PCSK9 and cholesterol levels in non-human primates in a late-breaking oral presentation at the 2023 American Heart Association (AHA) Scientific Sessions, held November 11-13 in Philadelphia. The data presented provide strong evidence for the potential of Chroma’s epigenetic editing platform to silence expression of PCSK9 in the liver and to induce a durable reduction in low-density lipoprotein-cholesterol (LDL-C) levels, a key factor for reducing…